Protective effects of D-002 on experimentally induced gastroesophageal reflux in rats

World Journal of Gastroenterology

Volumn 20, Issue 8, 2014, Pages 2085-2090

  Zamora, Zullyt ^a   Molina, Vivian ^a   Mas, Rosa ^a   Ravelo, Yazmin ^a   Perez, Yohany ^a   Oyarzabal, Ambar ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Beeswax alcohols; D 002; Esophagitis; Gastroesophageal reflux; Oxidative stress

Indexed keywords

BEESWAX ALCOHOL; MALONALDEHYDE; OMEPRAZOLE; PROPOLIS; UNCLASSIFIED DRUG; ANTIOXIDANT; ANTIULCER AGENT; D 002; FATTY ALCOHOL; OXYGEN; WAX;

ACIDITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIGESTIVE TRACT PARAMETERS; DRUG DOSE COMPARISON; ESOPHAGEAL LESION INDEX SCORE; GASTRIC SECRETION VOLUME; GASTROESOPHAGEAL REFLUX; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATION; PROTEIN OXIDATION; RAT; STOMACH SECRETION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; ESOPHAGUS; METABOLISM; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; REPRODUCIBILITY; SECRETION (PROCESS); SPRAGUE DAWLEY RAT; STOMACH ACID; STOMACH JUICE;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ULCER AGENTS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; ESOPHAGUS; FATTY ALCOHOLS; GASTRIC ACID; GASTRIC JUICE; GASTROESOPHAGEAL REFLUX; MALE; OMEPRAZOLE; OXIDATIVE STRESS; OXYGEN; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; WAXES;

EID: 84894575668     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i8.2085     Document Type: Article

References (42)

1. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005; 54: 710-717 [PMID: 15831922]
2. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, Dibonaventura MD, Carroll CF, Allen JK, Cook SF, Sandler RS, Kappelman MD, Shaheen NJ. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143: 1179-87. e1-3 [PMID: 22885331 DOI: 10.1053/j.gastro.2012.08.002]
3. Tytgat GN. Recent developments in gastroesophageal reflux disease and Barrett's esophagus: ANNO 2012. J Dig Dis 2012; 13: 291-295 [PMID: 22624551 DOI: 10.1111/j.1751-2980.2012.00598]
4. Martín-de-Argila C, Martínez-Jiménez P. Epidemiological study on the incidence of gastroesophageal reflux disease symptoms in patients in acute treatment with NSAIDs. Expert Rev Gastroenterol Hepatol 2013; 7: 27-33 [PMID: 23265146 DOI: 10.1586/egh.12.61]
5. Al Talalwah N, Woodward S. Gastro-oesophageal reflux. Part 1: smoking and alcohol reduction. Br J Nurs 2013; 22: 140-142, 144-146 [PMID: 23411821]
6. Kato M. [Gastroesophageal reflux disease (GERD). Barrett esophagus]. Nihon Rinsho 2009; 67: 2357-2365 [PMID: 19999125]
7. Kahrilas PJ, Lee TJ. Pathophysiology of gastroesophageal reflux disease. Thorac Surg Clin 2005; 15: 323-333 [PMID: 16104123]
8. Fox M, Forgacs I. Gastro-oesophageal reflux disease. BMJ 2006; 332: 88-93 [PMID: 16410582 DOI: 10.1136/bmj.332.7533.88]
9. Tsuboi K, Hoshino M, Sundaram A, Yano F, Mittal SK. Role of the lower esophageal sphincter on esophageal acid exposure-a review of over 2000 patients. Trop Gastroenterol 2012; 33: 107-111 [PMID: 23025056]
10. Nagahama K, Yamato M, Nishio H, Takeuchi K. Essential role of pepsin in pathogenesis of acid reflux esophagitis in rats. Dig Dis Sci 2006; 51: 303-309 [PMID: 16534673]
11. Yoshida N. Inflammation and oxidative stress in gastroesophageal reflux disease. J Clin Biochem Nutr 2007; 40: 13-23 [PMID: 18437209 DOI: 10.3164/jcbn.40.13]
12. Rieder F, Biancani P, Harnett K, Yerian L, Falk GW. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol 2010; 298: G571-G581 [PMID: 20299604 DOI: 10.1152/ajpgi.00454]
13. Kahrilas PJ, Shaheen NJ, Vaezi MF, Hiltz SW, Black E, Modlin IM, Johnson SP, Allen J, Brill JV. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135: 1383-1391, 1391. e1-5 [PMID: 18789939 DOI: 10.1053/j.gastro.2008.08.045]
14. Chubineh S, Birk J. Proton pump inhibitors: the good, the bad, and the unwanted. South Med J 2012; 105: 613-618 [PMID: 23128806 DOI: 10.1097/SMJ.0b013e31826efbea]
15. Dutta U, Armstrong D. Novel pharmaceutical approaches to reflux disease. Gastroenterol Clin North Am 2013; 42: 93-117 [PMID: 23452633 DOI: 10.1016/j.gtc.2012.12.001]
16. Chen J, Yuan YC, Leontiadis GI, Howden CW. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol 2012; 46: 93-114 [PMID: 22227731 DOI: 10.1097/ MCG.0b013e3182333820]
17. Desilets AR, Asal NJ, Dunican KC. Considerations for the use of proton-pump inhibitors in older adults. Consult Pharm 2012; 27: 114-120 [PMID: 22330952 DOI: 10.4140/TCP. n.2012.114]
18. Lau YT, Ahmed NN. Fracture risk and bone mineral density reduction associated with proton pump inhibitors. Pharmacotherapy 2012; 32: 67-79 [PMID: 22392829 DOI: 10.1002/ PHAR.1007]
19. Mas R. D-002: A product obtained from beeswax. Drug Future 2001; 26: 731-744
20. Carbajal D, Molina V, Valdés S, Arruzazabala L, Más R. Anti-ulcer activity of higher primary alcohols of beeswax. J Pharm Pharmacol 1995; 47: 731-733 [PMID: 8583384]
21. Carbajal D, Molina V, Valdés S, Arruzazabala L, Rodeiro I, Más R, Magraner J. Possible cytoprotective mechanism in rats of D-002, an anti-ulcerogenic product isolated from beeswax. J Pharm Pharmacol 1996; 48: 858-860 [PMID: 8887738]
22. Carbajal D, Molina V, Noa M, Valdés S, Arruzazabala ML, Aguilar C, Más R. Effect of D-002 on gastric mucus composition in ethanol-induced ulcer. Pharmacol Res 2000; 42: 329-332 [PMID: 10987992]
23. Molina V, Valdés S, Carbajal D, Arruzazabala L, Menéndez R, Más R. Antioxidant Effect of D-002 on Gastric Mucosa of Rats with Experimentally Induced Injury. J Med Food 2001; 4: 79-83 [PMID: 12639416]
24. Pérez Y, Oyárzabal A, Mas R, Molina V, Jiménez S. Protective effect of D-002, a mixture of beeswax alcohols, against indomethacin-induced gastric ulcers and mechanism of action. J Nat Med 2013; 67: 182-189 [PMID: 22576364 DOI: 10.1007/s11418-012-0670-y]
25. Inatomi N, Nagaya H, Takami K, Shino A, Satoh H. Effects of a proton pump inhibitor, AG-1749 (lansoprazole), on reflux esophagitis and experimental ulcers in rats. Jpn J Pharmacol 1991; 55: 437-451 [PMID: 1886289]
26. Pawlik M, Pajdo R, Kwiecien S, Ptak-Belowska A, Sliwowski Z, Mazurkiewicz-Janik M, Konturek SJ, Pawlik WW, potent esophagoprotection in experimental model of acute reflux esophagitis. Role of nitric oxide and proinflammatory cytokines. J Physiol Pharmacol 2011; 62: 75-86 [PMID: 21451212]
27. Konturek SJ, Zayachkivska O, Havryluk XO, Brzozowski T, Sliwowski Z, Pawlik M, Konturek PC, Cześnikiewicz-Guzik M, Gzhegotsky MR, Pawlik WW. Protective influence of melatonin against acute esophageal lesions involves prostaglandins, nitric oxide and sensory nerves. J Physiol Pharmacol 2007; 58: 361-377 [PMID: 17622703]
28. Markwell MA, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 1978; 87: 206-210 [PMID: 98070]
29. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358 [PMID: 36810]
30. Hu ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994; 233: 380-385 [PMID: 8015473]
31. Wetscher GJ, Perdikis G, Kretchmar DH, Stinson RG, Bagchi D, Redmond EJ, Adrian TE, Hinder RA. Esophagitis in Sprague-Dawley rats is mediated by free radicals. Dig Dis Sci 1995; 40: 1297-1305 [PMID: 7781451]
32. Meletis CD, Zabriskie N. Natural approaches for gastroesophageal reflux disease and related disorders. Altern Complemen Therap 2007; 13: 64-70 [DOI: 10.1089/act.2007.13204]
33. Biswas K, Bandyopadhyay U, Chattopadhyay I, Varadaraj A, Ali E, Banerjee RK. A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. J Biol Chem 2003; 278: 10993-11001 [PMID: 12529378]
34. Orlando LA, Lenard L, Orlando RC. Chronic hypergastrinemia: causes and consequences. Dig Dis Sci 2007; 52: 2482-2489 [PMID: 17415644]
35. Rodeiro I, Alemán C, Noa M, Menéndez R, Más R, Hernández C, Garcia M. Preclinical oral toxicology in rats of D-002, a natural drug with antiulcer effects. Drug Chem Toxicol 1998; 21: 151-162 [PMID: 9598297]
36. Alemán C, Rodeiro I, Noa M, Menéndez R, Gaméz R, Hernandez C, Más R. One-year dog toxicity study of D-002, a mixture of aliphatic alcohols. J Appl Toxicol 2001; 21: 179-184 [PMID: 11404829]
37. Menéndez R, Más R, Illnait J, Pérez J, Amor AM, Fernández JC, González RM. Effects of D-002 on Lipid Peroxidation in Older Subjects. J Med Food 2001; 4: 71-77 [PMID: 12639415]
38. Menéndez R, Más R, Amor AM, Pérez Y, González RM, Fernández J, Molina V, Jiménez S. Antioxidant effects of D002 on the in vitro susceptibility of whole plasma in healthy volunteers. Arch Med Res 2001; 32: 436-441 [PMID: 11578760]
39. López E, Illnait J, Molina V, Oyárzabal A, Fernández L, Pérez Y, Mas R., Mesa M, Fernández J, Mendoza S, Gómez M, Jiménez S, Ruiz D. Effects of D-002 (beeswax alcohols) on lipid peroxidation in middle-aged and older subjects. Lat Am J Pharm 2008; 27: 695-703
40. Fernández Dorta L, Terry H, Quiñones AM, Díaz B, Hernández ML, Mas JIR. Effects of Abexol® in middle-aged and older subjects: an open follow-up. Rev CENIC Cien Biol 2008; 39: 3-8
41. Illnait J, Rodríguez I, Molina V, Mendoza S, Mas R, Fernández L, Oyarzábal A, Pérez Y, Mesa M, Fernández JC, Gámez R, Jimenez S, Ruiz D, Cruz Y. Effects of D-002 (beeswax alcohols) on gastrointestinal symptoms and oxidative markers in middle-aged and older subjects. Lat Am J Pharm 2013; 32: 166-174
42. Illnait J, Rodríguez I, Mendoza S, Fernández Y, Mas R, Miranda M, Piñera J, Fernández JC, Mesa M, Fernández L, Carbajal D, Gámez R. Effects of D-002, a mixture of high molecular weight beeswax alcohols, on patients with nonalcoholic fatty liver disease. Korean J Intern Med 2013; 28: 439-448 [PMID: 23864802 DOI: 10.3904/kjim.2013.28.4.439]